Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

UNCOVERED: Abbvie files imbruvica us application for pediatric patients with chronic graft versus host disease - Caught on Camera

AbbVie Inc (NYSE:ABBV) has submitted a supplemental application to the FDA for Imbruvica (ibrutinib) for chronic graft versus host disease (cGVHD).

  • The application covers Imbruvica for pediatric and adolescent patients one year and older with cGVHD after the failure of one or more lines of systemic therapy. 
  • A New Drug Application (NDA) was also submitted for an oral suspension formulation of Imbruvica to provide an alternative administration option for pediatric patients. 
  • If approved, this represents AbbVie's first pediatric indication for Imbruvica.
  • Also See: AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings.
  • The iMAGINE trial enrolled 59 patients 1-19 years with relapsed/refractory (R/R) or new-onset moderate/severe cGVHD. Results showed an overall response rate of 78% with Imbruvica.
  • After 20 weeks, sustained response rates were observed in 70% and 58% of treatment-naive and R/R responders, respectively. 
  • In 2017, Imbruvica was first approved as a single-agent therapy for adult patients with cGVHD who have experienced failure of prior systemic treatment, becoming the first FDA-approved treatment for adults with cGVHD. 
  • Imbruvica could be the first FDA-approved BTKi treatment option for pediatric and adolescent patients with cGVHD.
  • Price Action: ABBV shares are down 1.83% at $146.75 during the market session on the last check Monday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.